BioNTech SE (BNTX) Non-Current Assets (2018 - 2025)
BioNTech SE (BNTX) posted Non-Current Assets of $6.8 billion for Q4 2025, up 5.56% on a QoQ basis from $6.4 billion in Q3 2025, and up 70.79% year-over-year from $4.0 billion in Q4 2024.
BioNTech SE (BNTX) has 8 years of Non-Current Assets data on file, last reported at $6.8 billion in Q4 2025.
- In Q4 2025, Non-Current Assets rose 70.79% year-over-year to $6.8 billion; the TTM figure through Dec 2025 stood at $6.8 billion (up 70.79% YoY), while the FY2025 annual figure was $6.6 billion, up 65.76% from the prior year.
- Non-Current Assets advanced to $6.8 billion in Q4 2025, from $6.4 billion in the prior quarter.
- Across five years, Non-Current Assets topped out at $6.8 billion in Q4 2025 and bottomed at $803.3 million in Q3 2021.
- A 5-year average of $3.2 billion and a median of $3.5 billion in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets jumped 224.44% — and 2024, when it increased 6.37%.
- Year by year, Non-Current Assets stood at $867.7 million in 2021, then soared by 59.57% to $1.4 billion in 2022, then soared by 170.35% to $3.7 billion in 2023, then rose by 6.37% to $4.0 billion in 2024, then soared by 70.79% to $6.8 billion in 2025.
- The last three Non-Current Assets figures came in at $6.8 billion (Q4 2025), $6.4 billion (Q3 2025), and $6.5 billion (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | BioNTech SE | 27.66 Bn | 7.53 Bn | 668.28 Mn | 6.80 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.80 Bn |
| Sep 30, 2025 | 6.44 Bn |
| Jun 30, 2025 | 6.46 Bn |
| Mar 31, 2025 | 5.85 Bn |
| Dec 31, 2024 | 3.98 Bn |
| Sep 30, 2024 | 4.30 Bn |
| Jun 30, 2024 | 4.26 Bn |
| Mar 31, 2024 | 4.33 Bn |
| Dec 31, 2023 | 3.74 Bn |
| Sep 30, 2023 | 3.76 Bn |
| Jun 30, 2023 | 3.28 Bn |
| Mar 31, 2023 | 2.14 Bn |
| Dec 31, 2022 | 1.38 Bn |
| Sep 30, 2022 | 1.40 Bn |
| Jun 30, 2022 | 1.01 Bn |
| Mar 31, 2022 | 935.47 Mn |
| Dec 31, 2021 | 867.70 Mn |
| Sep 30, 2021 | 803.33 Mn |
| Jun 30, 2021 | 854.19 Mn |
| Mar 31, 2021 | 806.61 Mn |
| Dec 31, 2020 | 777.02 Mn |
| Sep 30, 2020 | 417.49 Mn |
| Jun 30, 2020 | 388.08 Mn |
| Mar 31, 2020 | 264.23 Mn |
| Dec 31, 2019 | 262.88 Mn |
| Sep 30, 2019 | 263.84 Mn |
| Dec 31, 2018 | 232.87 Mn |